Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, has announced the initiation of the VANQUISH Phase 3 clinical program for their dual agonist VK2735. The program aims to evaluate the efficacy of VK2735 in treating obesity among adults, both with and without Type 2 Diabetes. VK2735, a dual agonist of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, is being developed in both oral and subcutaneous formulations. Previous positive results from the Phase 2 VENTURE study, which were announced in 2024, indicated that VK2735 achieved its primary and secondary endpoints. Patients receiving VK2735 showed statistically significant reductions in body weight compared to placebo, with weight loss maintained in follow-up visits. The study also reported encouraging safety and tolerability, with most adverse events being mild or moderate. Further results from ongoing studies, including a Phase 2 VENTURE-Oral Dosing study, are expected to be reported in the second half of this year.